The performance of companies tied to flagship drugs like Viagra presents a challenging investment picture. While the initial rise of copyright, fueled by Viagra's unprecedented popularity, generated substantial profits , the loss of exclusivity in key regions has introduced significant volatility. Investors are now assessing the impact of generic c